ALCLS.PA
Cellectis SA
Price:  
1.39 
EUR
Volume:  
77,556.00
France | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

ALCLS.PA WACC - Weighted Average Cost of Capital

The WACC of Cellectis SA (ALCLS.PA) is 6.4%.

The Cost of Equity of Cellectis SA (ALCLS.PA) is 8.35%.
The Cost of Debt of Cellectis SA (ALCLS.PA) is 5.50%.

Range Selected
Cost of equity 7.20% - 9.50% 8.35%
Tax rate 25.90% - 27.10% 26.50%
Cost of debt 4.00% - 7.00% 5.50%
WACC 5.3% - 7.6% 6.4%
WACC

ALCLS.PA WACC calculation

Category Low High
Long-term bond rate 3.0% 3.5%
Equity market risk premium 5.8% 6.8%
Adjusted beta 0.72 0.81
Additional risk adjustments 0.0% 0.5%
Cost of equity 7.20% 9.50%
Tax rate 25.90% 27.10%
Debt/Equity ratio 0.79 0.79
Cost of debt 4.00% 7.00%
After-tax WACC 5.3% 7.6%
Selected WACC 6.4%

ALCLS.PA's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for ALCLS.PA:

cost_of_equity (8.35%) = risk_free_rate (3.25%) + equity_risk_premium (6.30%) * adjusted_beta (0.72) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.